Cargando…

NFAT signalling is a novel target of oncogenic BRAF in metastatic melanoma

BACKGROUND: Metastatic melanoma is the most deadly form of skin cancer and with an overall 5-year survival rate of <11%, there is an acute need for novel therapeutic strategies. Activating mutations in the BRAF oncogene are present in 50–70% of cases and contribute to tumourigenesis, thus, defini...

Descripción completa

Detalles Bibliográficos
Autores principales:	Flockhart, R J, Armstrong, J L, Reynolds, N J, Lovat, P E
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2009
Materias:	Genetics and Genomics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768445/ https://www.ncbi.nlm.nih.gov/pubmed/19724275 http://dx.doi.org/10.1038/sj.bjc.6605277

Ejemplares similares

Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice
por: Heinzerling, L, et al.
Publicado: (2013)

Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer
por: Seppälä, T T, et al.
Publicado: (2015)

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
por: Loupakis, F, et al.
Publicado: (2009)

Lack of correlation between predicted and actual off-target effects of short-interfering RNAs targeting the human papillomavirus type 16 E7 oncogene
por: Hanning, J E, et al.
Publicado: (2013)

O(6)-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma
por: Ma, S, et al.
Publicado: (2003)

Biological activity of the thyroid TRK-T3 oncogene requires signalling through Shc
por: Roccato, E, et al.
Publicado: (2002)

Exceptional Clinical Response to BRAF-Targeted Therapy in a Patient with Metastatic Sarcoma
por: Mitsis, Demytra, et al.
Publicado: (2015)

Identification of 33 candidate oncogenes by screening for base-specific mutations
por: Tuupanen, S, et al.
Publicado: (2014)

Tumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma
por: Buechner, J, et al.
Publicado: (2011)

BRAF mutations and phosphorylation status of mitogen-activated protein kinases in the development of flat and depressed-type colorectal neoplasias
por: Konishi, K, et al.
Publicado: (2006)

Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer
por: Quaye, L, et al.
Publicado: (2009)

NFAT regulates induction of COX-2 and apoptosis of keratinocytes in response to ultraviolet radiation exposure
por: Flockhart, R. J., et al.
Publicado: (2008)

Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer
por: Kojima, S, et al.
Publicado: (2012)

Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk
por: Stevens, K N, et al.
Publicado: (2011)

A novel polymorphism in the 1A promoter region of the vitamin D receptor is associated with altered susceptibilty and prognosis in malignant melanoma
por: Halsall, J A, et al.
Publicado: (2004)

Role of MC1R variants in uveal melanoma
por: Hearle, N, et al.
Publicado: (2003)

Targeting the Cellular Signaling: BRAF Inhibition and Beyond for the Treatment of Metastatic Malignant Melanoma
por: Ades, Felipe, et al.
Publicado: (2012)

Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridisation and immunohistochemical analyses
por: Blancato, J, et al.
Publicado: (2004)

BRAF Testing in Melanoma and Colorectal Cancer in Latin America: Challenges and Opportunities
por: Peixoto, Renata D, et al.
Publicado: (2022)

EWS-Oct-4B, an alternative EWS-Oct-4 fusion gene, is a potent oncogene linked to human epithelial tumours
por: Kim, S, et al.
Publicado: (2010)

Strong reduction of AGO2 expression in melanoma and cellular consequences
por: Völler, D, et al.
Publicado: (2013)

miR-524-5p suppresses the growth of oncogenic BRAF melanoma by targeting BRAF and ERK2
por: Liu, Szu-Mam, et al.
Publicado: (2014)

Germline mutations of the INK4a-ARF gene in patients with suspected genetic predisposition to melanoma
por: Soufir, N, et al.
Publicado: (2004)

Fateful music from a talented orchestra with a wicked conductor: Connection between oncogenic BRAF, ER stress, and autophagy in human melanoma
por: Giglio, Paola, et al.
Publicado: (2015)

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
por: Spagnolo, Francesco, et al.
Publicado: (2014)

Can a genetic signature for metastatic head and neck squamous cell carcinoma be characterised by comparative genomic hybridisation?
por: Patmore, H S, et al.
Publicado: (2004)

Genotranscriptomic meta-analysis of the Polycomb gene CBX2 in human cancers: initial evidence of an oncogenic role
por: Clermont, P-L, et al.
Publicado: (2014)

XPD gene polymorphism and host characteristics in the association with cutaneous malignant melanoma risk
por: Baccarelli, A, et al.
Publicado: (2004)

Lithium Regulates Keratinocyte Proliferation Via Glycogen Synthase Kinase 3 and NFAT2 (Nuclear Factor of Activated T Cells 2)
por: Hampton, Philip J, et al.
Publicado: (2012)

Linkage and association analysis of nevus density and the region containing the melanoma gene CDKN2A in UK twins
por: Barrett, J H, et al.
Publicado: (2003)

MC1R gene variants and non-melanoma skin cancer: a pooled-analysis from the M-SKIP project
por: Tagliabue, E, et al.
Publicado: (2015)

Copper is required for oncogenic BRAF signaling and tumorigenesis
por: Brady, Donita C., et al.
Publicado: (2014)

The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma
por: Lesueur, F, et al.
Publicado: (2008)

KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer
por: Birkeland, E, et al.
Publicado: (2012)

ERK5 is activated by oncogenic BRAF and promotes melanoma growth
por: Tusa, Ignazia, et al.
Publicado: (2018)

Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma
por: Ryu, Sunhyo, et al.
Publicado: (2017)

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015)

Variants of the long control region and the E6 oncogene in European human papillomavirus type 16 isolates: implications for cervical disease
por: Kämmer, C, et al.
Publicado: (2002)

Microarray comparative genomic hybridisation analysis of intraocular uveal melanomas identifies distinctive imbalances associated with loss of chromosome 3
por: Hughes, S, et al.
Publicado: (2005)

LY6K is a novel molecular target in bladder cancer on basis of integrate genome-wide profiling
por: Matsuda, R, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_43tatlbh9l5mphpr52a50emvm6